Announced Mon, 25 May · 14:08 IST

We hereby submit Audited Financial Results for Q4 and FY2026

Revenue Growth 20pctPat Growth 25pctAuditor Mid Year ChangeResults View source PDF

YATHARTH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-4.8%1-day move
₹860.20
prior close
₹873.75
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-5.4-5.7-5.8-6.6-4.8-5.3-8.2-8.2-5.4-5.8-3.9-2.8-1.8
Up moveDown movePending
AI summary

Yatharth Hospital reported strong audited results for FY2026 with standalone revenue of ₹5,919 million (up 30% YoY) and consolidated revenue of ₹12,072 million (up 36% YoY). Standalone PAT grew 9% to ₹954 million while consolidated PAT grew 30% to ₹1,703 million. EPS improved to ₹18.20 per share on consolidated basis. The company has expanded its bed capacity significantly — a new 300-bed hospital in Delhi started in July 2025, a 400-bed hospital in Faridabad in September 2025, and a 150-bed hospital in Agra in February 2026. Finance costs increased sharply (standalone: ₹6.16M to ₹57.31M) reflecting higher debt to fund expansion. Auditors MSKA & Associates issued an unmodified opinion on both standalone and consolidated results.

Likely market impact

Strong top-line growth of 30-36% YoY reflects successful hospital expansion. PAT growth of 30% on consolidated basis is solid. Rising finance costs and increased borrowings indicate leverage being used for growth — investors should monitor debt levels and integration of new hospitals.